ArticleCritical care (London, England)2015
Persistently elevated osteopontin serum levels predict mortality in critically ill patients.
Article in Critical care (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 49 citations in OpenAlex.
- Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery.International journal of molecular sciences · 2017Trial
- Electrolyte and mineral disturbances in septic acute kidney injury patients undergoing continuous renal replacement therapy.Medicine · 2016Trial
- Article
- Osteopontin in Chronic Inflammatory Diseases: Mechanisms, Biomarker Potential, and Therapeutic Strategies.Biology · 2025Review
- Osteopontin and Clinical Outcomes in Hemodialysis Patients.Biomedicines · 2024Article
- Interorgan communication networks in the kidney-lung axis.Nature reviews. Nephrology · 2024Review
- Immunoregulatory Roles of Osteopontin in Diseases.Nutrients · 2024Review
- Osteopontin is a prognostic circulating biomarker in patients with neuroendocrine neoplasms.Journal of cancer research and clinical oncology · 2023Article
- Exogenously delivered iPSCs disrupt the natural repair response of endogenous MPCs after bone injury.Scientific reports · 2023Article
- Janus porous polylactic acid membranes with versatile metal-phenolic interface for biomimetic periodontal bone regeneration.NPJ Regenerative medicine · 2023Article
- COVID-19 Biomarkers at the Crossroad between Patient Stratification and Targeted Therapy: The Role of Validated and Proposed Parameters.International journal of molecular sciences · 2023Review
- Identification of kidney injury released circulating osteopontin as causal agent of respiratory failure.Science advances · 2022Article
- Secreted phosphoprotein 1 as a potential prognostic and immunotherapy biomarker in multiple human cancers.Bioengineered · 2022Article
- Mineral bone disorders and kidney disease in hospitalized children with sickle cell anemia.Frontiers in pediatrics · 2022Article
- Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19.Journal of clinical medicine · 2021Article
- A long journey for acute kidney injury biomarkers.Renal failure · 2020Review
- Reliability of biomarkers of sepsis during extracorporeal therapies: the clinician needs to know what is eliminated and what is not.Critical care (London, England) · 2020Article
- Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis.PloS one · 2020Article
- A Combined Score of Circulating miRNAs Allows Outcome Prediction in Critically Ill Patients.Journal of clinical medicine · 2019Article
- The Role of Osteopontin as a Diagnostic and Prognostic Biomarker in Sepsis and Septic Shock.Cells · 2019Observational
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
introductionInflammatory, autoimmune and metabolic disorders have been associated with alterations in osteopontin (OPN) serum levels. Furthermore, elevated serum levels of OPN were reported from a small cohort of patients with sepsis. We therefore analyzed OPN serum concentrations in a large cohort of critically ill medical patients.
methodsA total of 159 patients (114 with sepsis, 45 without sepsis) were studied prospectively upon admission to the medical intensive care unit (ICU) as well as after 3 days of ICU treatment and compared to 50 healthy controls. Clinical data, various laboratory parameters as well as investigational inflammatory cytokine profiles were assessed. Patients were followed for approximately 1 year.
resultsWe found significantly elevated serum levels of OPN at admission to the ICU and after 3 days of treatment in critically ill patients compared to healthy controls. OPN concentrations were related to disease severity and significantly correlated with established prognosis scores and classical as well as experimental markers of inflammation and multi-organ failure. In the total cohort, OPN levels decreased from admission to day 3 of ICU treatment. However, persistently elevated OPN levels at day 3 of ICU treatment were a strong independent predictor for an unfavorable prognosis, with similar or better diagnostic accuracy than routinely used markers of organ failure or prognostic scoring systems such as SAPS2 or APACHE II score.
conclusionsPersistently elevated OPN serum concentrations are associated with an unfavourable outcome in patients with critical illness, independent of the presence of sepsis. Besides a possible pathogenic role of OPN in critical illness, our study indicates a potential value for OPN as a prognostic biomarker in critically ill patients during the early course of ICU treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.